6PIL

Antibody scFv-M204 monomeric state

  • Classification: IMMUNE SYSTEM
  • Organism(s): Oryctolagus cuniculus
  • Expression System: Escherichia coli
  • Mutation(s): No 

  • Deposited: 2019-06-26 Released: 2020-06-24 
  • Deposition Author(s): Abskharon, R., Sawaya, M.R., Seidler, P.M., Cascio, D., Eisenberg, D.S.
  • Funding Organization(s): National Institutes of Health/National Human Genome Research Institute (NIH/NHGRI), National Institutes of Health/National Institute on Aging (NIH/NIA), National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS), Howard Hughes Medical Institute (HHMI)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.234 
  • R-Value Work: 0.194 
  • R-Value Observed: 0.198 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.

Abskharon, R.Seidler, P.M.Sawaya, M.R.Cascio, D.Yang, T.P.Philipp, S.Williams, C.K.Newell, K.L.Ghetti, B.DeTure, M.A.Dickson, D.W.Vinters, H.V.Felgner, P.L.Nakajima, R.Glabe, C.G.Eisenberg, D.S.

(2020) J Biol Chem 295: 10662-10676

  • DOI: https://doi.org/10.1074/jbc.RA120.013638
  • Primary Citation of Related Structures:  
    6PIL, 6PK8, 6PSC

  • PubMed Abstract: 

    Soluble oligomers of aggregated tau accompany the accumulation of insoluble amyloid fibrils, a histological hallmark of Alzheimer disease (AD) and two dozen related neurodegenerative diseases. Both oligomers and fibrils seed the spread of Tau pathology, and by virtue of their low molecular weight and relative solubility, oligomers may be particularly pernicious seeds. Here, we report the formation of in vitro tau oligomers formed by an ionic liquid (IL15). Using IL15-induced recombinant tau oligomers and a dot blot assay, we discovered a mAb (M204) that binds oligomeric tau, but not tau monomers or fibrils. M204 and an engineered single-chain variable fragment (scFv) inhibited seeding by IL15-induced tau oligomers and pathological extracts from donors with AD and chronic traumatic encephalopathy. This finding suggests that M204-scFv targets pathological structures that are formed by tau in neurodegenerative diseases. We found that M204-scFv itself partitions into oligomeric forms that inhibit seeding differently, and crystal structures of the M204-scFv monomer, dimer, and trimer revealed conformational differences that explain differences among these forms in binding and inhibition. The efficiency of M204-scFv antibodies to inhibit the seeding by brain tissue extracts from different donors with tauopathies varied among individuals, indicating the possible existence of distinct amyloid polymorphs. We propose that by binding to oligomers, which are hypothesized to be the earliest seeding-competent species, M204-scFv may have potential as an early-stage diagnostic for AD and tauopathies, and also could guide the development of promising therapeutic antibodies.


  • Organizational Affiliation

    Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute UCLA, Los Angeles, California, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
scFv-M204 antibody257Oryctolagus cuniculusMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.234 
  • R-Value Work: 0.194 
  • R-Value Observed: 0.198 
  • Space Group: P 41 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 60.42α = 90
b = 60.42β = 90
c = 159.42γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
XSCALEdata scaling
PHASERphasing
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Human Genome Research Institute (NIH/NHGRI)United States1R01 AG029430
National Institutes of Health/National Human Genome Research Institute (NIH/NHGRI)United StatesRF1 AG054022
National Institutes of Health/National Institute on Aging (NIH/NIA)United States1F32 NS095661
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United States1F32 NS095661
Howard Hughes Medical Institute (HHMI)United States--

Revision History  (Full details and data files)

  • Version 1.0: 2020-06-24
    Type: Initial release
  • Version 1.1: 2020-08-12
    Changes: Database references